Characteristics of detectable pre-HCT mosaicism in ALL patients. (A) Genomic location and type of detectable mosaicism among ALL patients. (B) Patient with cytogenetic abnormalities at diagnosis and detectable mosaicisms. ¹No detailed cytogenetics report at diagnosis. ²Complex chromosome aberration in the major histocompatibility complex region. (C) Probability of OS 1 year post-HCT in ALL patients. (D) Probability of OS 1 year post-HCT in patients with cytogenetic abnormalities. (E) Probability of OS 1 year post-HCT in patients with normal cytogenetics. (F) Cumulative incidence of relapse 1 year post-HCT in ALL patients. (G) Cumulative incidence of relapse 1 year post-HCT in patients with cytogenetic abnormalities. (H) Cumulative incidence of relapse 1 year post-HCT in patients with normal cytogenetics. TRM, transplant-related mortality.